Paul Rothenberg, MD, PhD
Paul Rothenberg, MD, PhD, is the Executive Director of Fortrea's Rare Diseases, Advanced Therapies and Pediatrics Team (RAPT). He has more than 25 years of pharmaceutical and CRO experience including Phase I-IV, translational medicine, clinical pharmacology. His expertise spans metabolic, renal and CV diseases. He also has supported pharmaceutical business development, scientific/medical evaluations of drug candidates for in-licensing, and cross-company collaborations.
Before joining Fortrea, Dr. Rothenberg was the Executive Director of Clinical Development Strategy at Labcorp. His previous leadership positions included leading the early clinical development group and the Translational Medicine group in the Cardiovascular/Metabolic Diseases department at Janssen (Johnson & Johnson), where he contributed to the development and lifecycle management of Invokana®, the first sodium-linked glucose transporter inhibitor (SGLT2i) approved for the treatment of diabetes.
